Overview
- U.S. regulators cleared Wegovy for metabolic dysfunction‑associated steatohepatitis, adding a liver disease indication to the brand.
- An oral formulation of semaglutide won approval for weight loss, becoming the first oral GLP‑1 therapy authorized for obesity.
- A higher‑dose injectable Wegovy is still under regulatory review, pointing to potential additional label expansion.
- Madrigal’s Rezdiffra generated $287.3 million in Q3 2025, highlighting the commercial potential of the MASH category Wegovy now enters.
- Novo Nordisk lost GLP‑1 market share to Eli Lilly in 2025, and the new approvals are expected to help reaccelerate sales in 2026.